Antony Attia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antony Attia has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Kazunari Sasaki
Stanford Transplant Outcomes Research Center (STORC), Division of Abdominal Transplantation, Stanford University Medical Center, Stanford, California
11 shared publications - Toshihiro Nakayama
Stanford University
9 shared publications - Daniel Jaechul Ahn
Stanford Transplant Outcomes Research Center (STORC), Division of Abdominal Transplantation Stanford University Medical Center Stanford California USA
8 shared publications - Kiran K. Khush
Stanford University
4 shared publications - Marc L. Melcher
Department of Surgery, Stanford University, Palo Alto, CA, USA
4 shared publications - Nikhil Narang
The University of Chicago
3 shared publications
Latest Publications
- Open Access
- 19 September 2026
- Published by Elsevier in American Journal of Transplantation
In policy and in practice: expedited placement and allocation out-of-sequence in liver transplantation
- 19 September 2026
- Published by Elsevier in American Journal of Transplantation
Open AccessIn policy and in practice: expedited placement and allocation out-of-sequence in liver transplantation
- 14 August 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (8) , e70641
The Benefit of Sequential Normothermic Regional Perfusion and Hypothermic Machine Perfusion in Kidney Transplantation From Donation After Circulatory Death Donors
Background: Normothermic regional perfusion (NRP) is associated with improved posttransplant outcomes in donation after circulatory death (DCD) kidney transplantation. It remains unknown whether hypothermic machine perfusion (HMP) offers additional benefits over static cold storage (SCS) during transport. Methods: All adult kidney‐only transplantations from DCD donors procured by NRP in the OPTN data (10/1/2020‐6/30/2025) were identified. Primary exposure was preservation method during transport: NRP combined with HMP (NRP+HMP) or SCS (NRP+SCS). One‐to‐two propensity score matching (PSM) was performed on fifteen donor and recipient factors. Primary outcomes included delayed graft function (DGF), posttransplant length of stay (LOS), and estimated glomerular filtration rate (eGFR) at 6 months posttransplant. Secondary outcomes were one‐year graft and patient survival. Results: Among 4792 NRP cases, HMP was utilized in 85.1%, with its use increasing over time. After 1:2 PSM (685 NRP+SCS matched to 1262 NRP+HMP), NRP+HMP was associated with significantly lower DGF (23.3% vs. 30.5%, p < 0.01). Median LOS (4.0 days in both groups, p = 0.07), 6‐month eGFR (58.5 vs. 60.1 mL/min/1.73m 2 , p = 0.46), one‐year graft survival, and one‐year patient survival were not significantly different. The association between HMP and lower DGF was observed across KDPI strata, heart recovery status, and cold ischemia time categories, with no significant interactions detected. Conclusion: The adoption of HMP after NRP has increased substantially in the United States and was associated with reduced DGF, but no difference was observed for LOS, 6‐month eGFR, graft survival, and patient survival. These findings support the routine use of HMP after NRP.
- 14 August 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (8) , e70641
The Benefit of Sequential Normothermic Regional Perfusion and Hypothermic Machine Perfusion in Kidney Transplantation From Donation After Circulatory Death Donors
Background: Normothermic regional perfusion (NRP) is associated with improved posttransplant outcomes in donation after circulatory death (DCD) kidney transplantation. It remains unknown whether hypothermic machine perfusion (HMP) offers additional benefits over static cold storage (SCS) during transport. Methods: All adult kidney‐only transplantations from DCD donors procured by NRP in the OPTN data (10/1/2020‐6/30/2025) were identified. Primary exposure was preservation method during transport: NRP combined with HMP (NRP+HMP) or SCS (NRP+SCS). One‐to‐two propensity score matching (PSM) was performed on fifteen donor and recipient factors. Primary outcomes included delayed graft function (DGF), posttransplant length of stay (LOS), and estimated glomerular filtration rate (eGFR) at 6 months posttransplant. Secondary outcomes were one‐year graft and patient survival. Results: Among 4792 NRP cases, HMP was utilized in 85.1%, with its use increasing over time. After 1:2 PSM (685 NRP+SCS matched to 1262 NRP+HMP), NRP+HMP was associated with significantly lower DGF (23.3% vs. 30.5%, p < 0.01). Median LOS (4.0 days in both groups, p = 0.07), 6‐month eGFR (58.5 vs. 60.1 mL/min/1.73m 2 , p = 0.46), one‐year graft survival, and one‐year patient survival were not significantly different. The association between HMP and lower DGF was observed across KDPI strata, heart recovery status, and cold ischemia time categories, with no significant interactions detected. Conclusion: The adoption of HMP after NRP has increased substantially in the United States and was associated with reduced DGF, but no difference was observed for LOS, 6‐month eGFR, graft survival, and patient survival. These findings support the routine use of HMP after NRP.
- Open Access
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e013854
Potential Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates With Durable LVADs
BACKGROUND: The 2018 heart allocation policy change substantially lowered the priority of candidates supported with durable left ventricular assist devices (LVADs) for heart transplantation. To provide stable candidates supported by durable LVADs with a quicker path to transplantation before they suffer complications, the Organ Procurement and Transplantation Network (OPTN) approved a policy stipulating that stable patients supported by durable LVADs for 6 and 8 years will obtain statuses 3 and 2, respectively. METHODS: Using OPTN data, we identified all adult heart transplant candidates with a durable LVAD implanted between October 18, 2018 and May 31, 2025. We estimated the cumulative incidence of LVAD-related complications, treating transplantation and waitlist removal before experiencing complications as competing events. Furthermore, we assessed how the OPTN policy change would impact the status distribution of the waitlist. RESULTS: In our study cohort, 4967 adult patients who were listed for heart transplant received a durable LVAD. Transplant centers submitted 2879 justifications for status upgrades due to LVAD-related complications for 1812 (36.5%) patients. At 6 years after durable LVAD implantation, the cumulative incidence of complications and status upgrades was 42.1% (95% CI, 40.5%–43.8%), and that of transplantation was 36.0% (95% CI, 34.6%–37.6%). Of the 3779 patients who were not censored administratively, only 47 (1.2%) remained on the waitlist by 6 years after durable LVAD implantation. Had the 6- to 8-year OPTN policy change been implemented on June 1, 2025, only 4.7% of the waitlist would have changed statuses instantaneously. CONCLUSIONS: Almost all listed candidates with durable LVADs either experience a complication, status upgrade or are removed from the waitlist within 6 years of obtaining a durable LVAD. The upcoming OPTN policy is unlikely to prevent device complications before granting status upgrades and will likely impact a small percentage of candidates with durable LVADs.
- 23 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e013854
Open AccessPotential Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates With Durable LVADs
BACKGROUND: The 2018 heart allocation policy change substantially lowered the priority of candidates supported with durable left ventricular assist devices (LVADs) for heart transplantation. To provide stable candidates supported by durable LVADs with a quicker path to transplantation before they suffer complications, the Organ Procurement and Transplantation Network (OPTN) approved a policy stipulating that stable patients supported by durable LVADs for 6 and 8 years will obtain statuses 3 and 2, respectively. METHODS: Using OPTN data, we identified all adult heart transplant candidates with a durable LVAD implanted between October 18, 2018 and May 31, 2025. We estimated the cumulative incidence of LVAD-related complications, treating transplantation and waitlist removal before experiencing complications as competing events. Furthermore, we assessed how the OPTN policy change would impact the status distribution of the waitlist. RESULTS: In our study cohort, 4967 adult patients who were listed for heart transplant received a durable LVAD. Transplant centers submitted 2879 justifications for status upgrades due to LVAD-related complications for 1812 (36.5%) patients. At 6 years after durable LVAD implantation, the cumulative incidence of complications and status upgrades was 42.1% (95% CI, 40.5%–43.8%), and that of transplantation was 36.0% (95% CI, 34.6%–37.6%). Of the 3779 patients who were not censored administratively, only 47 (1.2%) remained on the waitlist by 6 years after durable LVAD implantation. Had the 6- to 8-year OPTN policy change been implemented on June 1, 2025, only 4.7% of the waitlist would have changed statuses instantaneously. CONCLUSIONS: Almost all listed candidates with durable LVADs either experience a complication, status upgrade or are removed from the waitlist within 6 years of obtaining a durable LVAD. The upcoming OPTN policy is unlikely to prevent device complications before granting status upgrades and will likely impact a small percentage of candidates with durable LVADs.
- Open Access
- 22 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e013994
High Rate of Transplantation Before Review of Status Exception Requests Among Adult Heart Transplant Candidates
BACKGROUND: In the US heart allocation system, when transplant centers submit applications for status exceptions to increase waitlist priority, patients obtain the requested status upgrades immediately while their applications are sent to the regional review boards (RRBs) and reviewed retrospectively. How often transplants occur during this period is unknown. METHODS: Using the Scientific Registry of Transplant Recipients, we identified all adult heart transplant candidates listed between October 18, 2018, and May 31, 2025, with submitted applications for status exceptions. We assessed (1) the time elapsed between submission of exception applications and their receipt by the RRBs and (2) the rate of heart transplantation during this travel time, stratified by whether the applications were eventually approved or denied. Additionally, we estimated how many listed patients were skipped by candidates who received transplants with exceptions that were ultimately denied. RESULTS: 138 transplant centers submitted status exception requests on behalf of 11 508 adult candidates during the study period, of whom 913 (7.9%) received a denial at least once. The median time from obtaining status upgrades to application receipt by the RRBs was 3 days. Three thousand seven out of 11 508 (26.1%) patients received transplants before the RRBs even received their applications, with 174 (19.1%) among 913 with eventual denials and 2833 (26.7%) among 10 595 with approvals. The cumulative incidence of heart transplantation before application receipt for eventual denials was 19.1% (95% CI, 16.6%–21.7%), and that for approvals was 27.2% (95% CI, 26.4%–28.0%; P <0.001) at 2 weeks. Candidates who received transplants despite being denied exceptions bypassed more than 11 thousand potential transplant recipients. CONCLUSIONS: More than 25% of patients with status exception requests receive heart transplants before their applications are even received by their RRBs, raising significant concerns about the fairness of retrospective review of exception requests for the allocation of donor hearts.
- 22 June 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (7) , e013994
Open AccessHigh Rate of Transplantation Before Review of Status Exception Requests Among Adult Heart Transplant Candidates
BACKGROUND: In the US heart allocation system, when transplant centers submit applications for status exceptions to increase waitlist priority, patients obtain the requested status upgrades immediately while their applications are sent to the regional review boards (RRBs) and reviewed retrospectively. How often transplants occur during this period is unknown. METHODS: Using the Scientific Registry of Transplant Recipients, we identified all adult heart transplant candidates listed between October 18, 2018, and May 31, 2025, with submitted applications for status exceptions. We assessed (1) the time elapsed between submission of exception applications and their receipt by the RRBs and (2) the rate of heart transplantation during this travel time, stratified by whether the applications were eventually approved or denied. Additionally, we estimated how many listed patients were skipped by candidates who received transplants with exceptions that were ultimately denied. RESULTS: 138 transplant centers submitted status exception requests on behalf of 11 508 adult candidates during the study period, of whom 913 (7.9%) received a denial at least once. The median time from obtaining status upgrades to application receipt by the RRBs was 3 days. Three thousand seven out of 11 508 (26.1%) patients received transplants before the RRBs even received their applications, with 174 (19.1%) among 913 with eventual denials and 2833 (26.7%) among 10 595 with approvals. The cumulative incidence of heart transplantation before application receipt for eventual denials was 19.1% (95% CI, 16.6%–21.7%), and that for approvals was 27.2% (95% CI, 26.4%–28.0%; P <0.001) at 2 weeks. Candidates who received transplants despite being denied exceptions bypassed more than 11 thousand potential transplant recipients. CONCLUSIONS: More than 25% of patients with status exception requests receive heart transplants before their applications are even received by their RRBs, raising significant concerns about the fairness of retrospective review of exception requests for the allocation of donor hearts.
- Open Access
- 9 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (11) , 1809-1817
Artifactual declines in durable LVAD utilization among heart transplant candidates: Selection bias in transplant registries
- 9 June 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (11) , 1809-1817
Open AccessArtifactual declines in durable LVAD utilization among heart transplant candidates: Selection bias in transplant registries
- 15 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (10) , 2336-2344
Highly sensitized pediatric kidney candidates have reduced access to kidney transplant in the United States
- 15 May 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (10) , 2336-2344
Highly sensitized pediatric kidney candidates have reduced access to kidney transplant in the United States
- 28 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1213-1214
Out-of-sequence or out of options? Rethinking liver allocation in a crisis of confidence
- 28 February 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1213-1214
Out-of-sequence or out of options? Rethinking liver allocation in a crisis of confidence
- 10 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1273-1283
Renal Resistance on Hypothermic Machine Perfusion and Acceptance of Deceased Donor Kidney Allografts
Key Points: Terminal renal resistance added prognostic value to kidney donor profile index (KDPI), especially in KDPI >0.85 kidneys. Its effect was modest in KDPI ≤0.85 kidneys. Terminal renal resistance was found to be useful in guiding the acceptance of KDPI >0.85 kidneys on the basis of estimated post-transplant survival. Terminal renal resistance ≥0.3 triggered kidney nonuse regardless of KDPI, but KDPI ≤0.85 kidneys should not be declined on the basis of resistance alone. Background: Elevated terminal renal resistance on hypothermic machine perfusion is widely regarded as a marker of kidney quality and a trigger for kidney nonuse for transplantation, yet large-scale evidence is limited on whether terminal renal resistance adds prognostic value beyond kidney donor profile index (KDPI). Methods: Adult kidney-only transplants performed using hypothermic machine perfusion ( n =36,490) in the Organ Procurement and Transplantation Network database between March 31, 2015, and December 31, 2023, were included. Terminal renal resistance was categorized as 0.85) kidneys. Utilization analyses were performed in a separate donor cohort of 15,524 kidneys recovered using hypothermic machine perfusion from eight organ procurement organizations. Results: Higher renal resistance was independently associated with worse 5-year graft survival (hazard ratio for graft loss=1.49 [≥0.4] versus P < 0.001). The effect was modest in KDPI 0.85 grafts. Renal resistance thresholds that were associated with better survival of using KDPI >0.85 kidneys differed on the basis of candidate estimated post-transplant survival (EPTS; renal resistance <0.2 for EPTS <0.35, <0.3 for EPTS 0.35–0.85, and 0.85). Utilization dropped sharply beyond a terminal renal resistance of 0.3 across all KDPI strata, disproportionate to the actual graft risk. Utilization of KDPI ≤0.85 grafts with renal resistance ≥0.30 could have yielded an estimated 357 (95% confidence interval, 304 to 377) additional transplants per year. Conclusions: Terminal renal resistance was associated with long-term graft and patient survival, but this effect was clinically meaningful only in high-KDPI kidneys.
- 10 December 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (6) , 1273-1283
Renal Resistance on Hypothermic Machine Perfusion and Acceptance of Deceased Donor Kidney Allografts
Key Points: Terminal renal resistance added prognostic value to kidney donor profile index (KDPI), especially in KDPI >0.85 kidneys. Its effect was modest in KDPI ≤0.85 kidneys. Terminal renal resistance was found to be useful in guiding the acceptance of KDPI >0.85 kidneys on the basis of estimated post-transplant survival. Terminal renal resistance ≥0.3 triggered kidney nonuse regardless of KDPI, but KDPI ≤0.85 kidneys should not be declined on the basis of resistance alone. Background: Elevated terminal renal resistance on hypothermic machine perfusion is widely regarded as a marker of kidney quality and a trigger for kidney nonuse for transplantation, yet large-scale evidence is limited on whether terminal renal resistance adds prognostic value beyond kidney donor profile index (KDPI). Methods: Adult kidney-only transplants performed using hypothermic machine perfusion ( n =36,490) in the Organ Procurement and Transplantation Network database between March 31, 2015, and December 31, 2023, were included. Terminal renal resistance was categorized as 0.85) kidneys. Utilization analyses were performed in a separate donor cohort of 15,524 kidneys recovered using hypothermic machine perfusion from eight organ procurement organizations. Results: Higher renal resistance was independently associated with worse 5-year graft survival (hazard ratio for graft loss=1.49 [≥0.4] versus P < 0.001). The effect was modest in KDPI 0.85 grafts. Renal resistance thresholds that were associated with better survival of using KDPI >0.85 kidneys differed on the basis of candidate estimated post-transplant survival (EPTS; renal resistance <0.2 for EPTS <0.35, <0.3 for EPTS 0.35–0.85, and 0.85). Utilization dropped sharply beyond a terminal renal resistance of 0.3 across all KDPI strata, disproportionate to the actual graft risk. Utilization of KDPI ≤0.85 grafts with renal resistance ≥0.30 could have yielded an estimated 357 (95% confidence interval, 304 to 377) additional transplants per year. Conclusions: Terminal renal resistance was associated with long-term graft and patient survival, but this effect was clinically meaningful only in high-KDPI kidneys.